Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of zolbetuximab re-challenge with nab-paclitaxel and ramucirumab in CLDN18.2-positive advanced gastric/EGJ cancer
jRCTs071250038Phase 2Recruiting
- Sponsor
- Astellas Pharma
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zolbetuximab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Astellas Pharma. Primary endpoints: Tolerability evaluation and Overall survival in the largest analysis population. Started Sep 2025; status: recruiting.
02
Drugs
zolbetuximab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCTs071250038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071250038.